Article: Schering-plough vies to quash generic OTC claritin. (Life Sciences).(Has filed separate suits against divisions of Johnson & Johnson and American Home Products Corp.)(Brief Article)

IN A MOVE to block generic over-the-counter (OTC) competition for its $3.2 billion antihistamine Claritin (loratadine) and lock-in sales of Clarinex (desloratadine), a newly launched successor, Schering-Plough Corp. (SHP) has filed separate suits against divisions of Johnson & Johnson (J&J) and American Home Products Corp. (AHP).

If victorious in an upcoming trial against generic firms seeking to market prescription loratadine, SHP will potentially impede generic prescription and OTC Claritin until October 2004. ABN Amro and Prudential Financial estimate patent expiration for Claritin in December 2002.

SHP charges the applications for OTC generic ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!